
- 21. (amended) The pharmaceutical composition of claim 14, wherein the composition is administered in the form selected from the group consisting of tablets, dragees, capsules, granules, solutions, suspensions and lyophilized compositions.
- 22. (amended) The pharmaceutical composition of claim 14 wherein the composition further comprises a fat-soluble antioxidant selected from the group consisting of ascorbyl palmitate, tocopherols, and ascorbic acid in the presence of lecithin.
- 23. (amended) The pharmaceutical composition of claim 14 wherein the composition further comprises an additive selected from the group consisting of aggregants, disaggregants, osmotic pressure regulating salts, buffers, sweeteners, and coloring agents.
- 27. (amended) The use of the pharmaceutical composition of claim 14 to treat:
  - (a) cardiovascular or cerebrovascular disease
  - (b) inflammatory or autoimmune disease
  - (c) infection with bacteria, viruses, fungi, or protozoa,
  - (d) respiratory disease
  - (e) gastrointestinal disease
  - (f) renal or urinary tract disease
  - (q) skin disease
  - (h) neurological or psychiatric disease
  - (i) disease of the reproductive system
  - (j) diabetes, syndrome A or any complication of diabetes



- 30. (amended) The use of the pharmaceutical composition of claim 14 to treat a disease or condition where endothelial function is disordered.
- 31. (amended) The use of the pharmaceutical composition of claim 14 to treat cancer or the metastatic spread of cancer.
- 32. (amended) The use of the pharmaceutical composition of claim 14 to prevent cancer or the metastatic spread of cancer.